Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

csl behring gmbh - human blood coagulation factor viii, human von willebrand factor (vwf:rco) - powder and solvent for solution for injection/ infusion - 500iu+1200iu

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

csl behring gmbh - human blood coagulation factor viii, human von willebrand factor (vwf:rco) - powder and solvent for solution for injection/ infusion - 1000iu+2400iu

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - von willebrand factor, quantity: 400 iu; factor viii, quantity: 7.5 mg; factor viii, quantity: 450 iu - injection, powder for - excipient ingredients: tributyl phosphate; sucrose; sodium citrate dihydrate; sodium chloride; calcium chloride dihydrate; octoxinol 9; glycine - 1. von willebrand disease (vwd): treatment of bleeding episodes including surgical bleeding in patients with von willebrand's disease when desmorpressin treatment is effective or contraindicated. 2. haemophilia a: treatment and prophylaxis of bleeding including surgical bleeding in patients with haemophilia a (congenital fviii deficiency). there are insifficient data to recommend the use of wilate in children less than 12 years of age.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

csl behring uk ltd - von willebrand factor; factor viii - powder and solvent for solution for injection - 2400unit ; 1000unit

Israel - English - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 500 iu/vial; von willebrand factor 1300 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

Israel - English - Ministry of Health

kamada ltd, israel - factor viii; von willebrand factor - powder for solution for injection - factor viii 1000 iu/vial; von willebrand factor 2600 iu/vial - von willebrand factor and coagula-tion factor viii in combination - von willebrand factor and coagula-tion factor viii in combination - treatment and prophylaxis of bleeding with haemophilia a (congenital factor viii deficiency).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - factor viii; von willebrand factor - powder and solvent for solution for injection - 500unit ; 1000unit

Singapore - English - HSA (Health Sciences Authority)

blood services group, health sciences authority - coagulation factor viii (human) (freeze-dried); von willebrand factor - injection, powder, for solution - 50 iu/ml - coagulation factor viii (human) (freeze-dried) 50 iu/ml; von willebrand factor 100 iu/ml

United States - English - NLM (National Library of Medicine)

octapharma usa inc - antihemophilic factor human (unii: 839moz74gk) (antihemophilic factor human - unii:839moz74gk), von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - antihemophilic factor human 100 [iu] in 1 ml - wilate is indicated in children and adults with von willebrand disease for: - on-demand treatment and control of bleeding episodes - perioperative management of bleeding wilate is indicated in adolescents and adults with hemophilia a for: - routine prophylaxis to reduce the frequency of bleeding episodes - on-demand treatment and control of bleeding episodes wilate is contraindicated in patients with known hypersensitivity reactions, including anaphylactic or severe systemic reactions, to human plasma-derived products, any ingredient in the formulation [see description (11) ] , or components of the container. risk summary there are no data with wilate use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with wilate. wilate was given to four subjects (3 type 3 and 1 type 2b) during labor and delivery in one clinical study. two subjects underwent vaginal delivery (type 3) and two subjects had a cesarean section (type 3/type 2b). in this study all pro

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii,von willebrand factor -